

ESGCT SPRING SCHOOL PROGRAMME

POTSDAM, GERMANY | 8-11 APRIL 2025

TUESDAY 8 APRIL

15:00-16:00	Registration
16:00-18:30	<u>Workshops</u> Workshop 1: How to give a convincing speech Paul Charlton, <i>Specialist expert speaker coach for international STEM professionals</i> Workshop 2: How to write a scientific manuscript Thomas Gallagher, <i>Human Gene Therapy</i> Workshop 3: How to create a spin-off (Entrepreneurship & how to make the best out of your inventions) Elke Luger, <i>National Network Office GCT Germany & BIH</i> ; Vincenzo Cerullo , <i>University of Helsinki</i>
19:00-22:00	Break the Ice Dinner @ Mercure Hotel

WEDNESDAY 9 APRIL

09:00-11:00	Welcome and Keynote Welcome Address: Alberto Auricchio (President, ESGCT); Zoltan Ivics (President, DG>); Hildegard Büning (ESGCT Education & Training) Keynote INV01: Christopher Baum , <i>BIH, Berlin</i> Developing an innovation ecosystem for gene therapy INV02: Claire Booth , <i>University College London</i> The challenge of accessibility and sustainability of gene therapy medicinal products
11:00-11:30	Coffee Break
11:30-13:30	Session 1: Gene therapy tools - what you should know about viral and non-viral vectors, part I INV03: Axel Schambach , <i>Hannover Medical School</i> Insights and challenges on how to design retroviral and lentiviral vectors INV04: Els Verhoeven , <i>EVIR, INSERM U758, Lyon; C3M, INSERM U1065, Nice</i> How to improve nature – the next generation of lentiviral vectors INV05: Hildegard Büning , <i>Hannover Medical School</i> Adeno-associated virus (AAV) vector system - the unusual career of non-autonomous parvovirus

13:30-15:00	Lunch Break (with Meet the Expert tables)
15:00-17:00	<p>Session 2: Gene therapy tools - what you should know about viral and non-viral vectors, part II</p> <p>INV06: Anja Ehrhardt, <i>Witten/Herdecke University</i> Adenovirus Vectors – a powerful tool in gene therapy and vaccine development</p> <p>INV07: Melanie Galla, <i>Hannover Medical School</i> Virus like particles – retroviral particles tailored to customer's needs</p> <p>INV08: Tristan Montier, <i>University of Brest</i> Strategies to improve non-viral vector mediated gene transfer</p>
17:00-17:15	Coffee Break
17:15-19:15	Guided tour of Potsdam
19:30	Dinner and social activity

THURSDAY 10 APRIL

09:00-10:00	<p>Keynote</p> <p>INV09: Alberto Auricchio, <i>TIGEM, Naples</i> AAV gene therapy from Bench to Bedside</p>
10:00-10:30	Coffee Break
10:30-12:30	<p>Session 3: Genome engineering & beyond – a plethora of possibilities</p> <p>INV10: Zoltan Ivics, <i>Fraunhofer IZI, Leipzig</i> Digging in the Dirt: How Archeogenetics and Synthetic Biology Revolutionized Gene Therapy</p> <p>INV11: Frank Buchholz, <i>TU Dresden</i> Site-specific recombinases, Swiss Army Knives in the genome engineering tool-box</p> <p>INV12: Claudio Mussolino, <i>University of Freiburg</i> The basics of Designer Nucleases and CRISPR-Cas-based gene editing</p>
12:30-14:00	Lunch Break
14:00-16:00	<p>Session 4: Beyond conventional CRISPR-Cas strategies</p> <p>INV13: Toni Cathomen, <i>University of Freiburg</i> Safety first – how to detect and minimize off-target effects</p> <p>INV14: Angelo Lombardo, <i>SR-Tiget, Milan</i> Programming gene silencing by epigenome editing</p> <p>INV15: Bernhard Gentner, <i>Ludwig Institute for Cancer Research, Lausanne</i> Genetically engineered hematopoietic stem cells as weapon</p>
16:00 -16:30	Coffee Break

16:30-19:00	<p>Session 5: Challenges in gene and cell therapy</p> <p>INV16: Anne Galy, ART-TG - Inserm US35 Immune system: friend or foe in gene therapy</p> <p>INV17: Gloria Gonzalez-Aseguinolaza, CIMA, University of Navarra, Pamplona Potential mechanism involved in AAV toxicity</p> <p>INV18: Serge Braun, AFM-Telethon One can change the world by selling pancakes and balloons - how patient organizations change the face of gene therapy</p> <p>Panel Discussion Serge Braun, Alberto Auricchio, Anne Galy, Gloria Gonzalez-Aseguinolaza, Christopher Baum, Paula Rio</p>
19:30	Social event and dinner

FRIDAY 11 APRIL

09:00-11:00	<p>Session 7: Novel approaches in fighting cancer</p> <p>INV19: Dirk M. Nettelbeck, German Cancer Research Center, Heidelberg Virotherapy of cancer – engineering viruses for tumor-targeted lysis, drug delivery and immunotherapy</p> <p>INV20: Manlio Fusciello, University of Helsinki Cancer Vaccines</p> <p>INV21: Hinrich Abken, University of Regensburg CAR T cell therapy – from bench to bedside and back</p>
11:00-11:30	Coffee Break
11:30-12:50	<p>Session 8: NK and T cells as versatile tools in gene therapy</p> <p>INV22: Britta Eiz-Vesper, Hannover Medical School Engineered T cells to fight infections</p> <p>INV23: Boris Fehse, University of Hamburg T cell approaches in anti-HIV treatment</p>
12:50-14:00	Lunch Break
14:00-16:00	<p>Session 9: Pre-clinical and clinical gene therapy</p> <p>INV24: Nathalie Cartier, AskBio, Paris Gene Therapy of the CNS</p> <p>INV25: Stylianos Michalakis, LMU Munich Retinal Gene Therapy</p> <p>INV26: Christian Kupatt, TU Munich Cardiovascular Gene Therapy</p> <p>INV27: Paula Rio, CIEMAT / CIBERER, Madrid Gene Therapy for Fanconi</p>
16:15-16:30	<p>Closing</p> <p>Alberto Auricchio, Hildegard Büning, Zoltan Ivics</p>